FDA warns about danger of Pfizer's Geodon; Proposed law would hasten antibiotic approvals;

@FiercePharma: Kansas State researchers model U.S. outbreak of foot-and-mouth. Story | Follow @FiercePharma

@CarlyHFierce: I think BOLERO-1 might be my favorite trial name ever. Release | Follow @CarlyHFierce

> Lupin has launched an approved generic of Pfizer's ($PFE) pain drug Celebrex in the U.S. Release

> Johnson & Johnson's ($JNJ) Janssen unit has donated about 30,000 doses of its multidrug-resistant tuberculosis-fighting treatment, $30 million worth, to the U.S. Agency for International Development. Release

> The FDA warned that the Geodon antipsychotic pill sold by Pfizer, as well as generic versions of the drug, can trigger a potentially fatal skin reaction. Release

> Two U.S. Senators are pushing for new legislation that would allow the FDA to approve some antibiotics through a special "limited use" procedure in an effort to get antibiotics that can fight antibiotic-resistant bacteria to market. Story

Medical Device News

@FierceMedDev: DARPA's ElectRx seeks innovators to transform neuromodulation devices. More | Follow @FierceMedDev

@EmilyWFierce: #India's NPPA extends pricing policy on drugs, adding fuel to price cap fire. Story | Follow @EmilyWFierce

> Judge advises Bard to settle vaginal mesh implant cases. Article

> Strong one-year data for Boston Scientific chronic pain implant, but reimbursement change stymies sales. More

> FDA works to improve medical device approval times. News

Biotech News

@FierceBiotech: EuroBiotech: Shire steps up arGEN-X alliance, Big Pharma gives MRC drugs, Woodford backs Midatech IPO. More | Follow @FierceBiotech

@DamianFierce: $BMRN's buyout subs are called Falcons and Giants, which could be an NFL thing or a ref to some obscure fantasy novel. More | Follow @DamianFierce

> Shire chief: We want to be like Gilead, Biogen and Celgene. News

> ChemoCentryx soars on new hope for its once-maligned kidney drug. Story

> Novartis' psoriasis drug tops J&J's Stelara as it speeds toward approval. Article

And Finally... The FDA is giving the University of Alabama at Birmingham permission to study the use of a marijuana derivative to treat seizures in children. Story

Suggested Articles

AstraZeneca and Brazil have expanded their deal for a possible COVID-19 vaccine, this time to the tune of $360 million.

Novavax expects to churn out enough vaccines in 2021 to meet U.S. demand; experts slam the medical and political risks of Russia's unproven vaccine.

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.